Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis

Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and <i>NPY1R</i> are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP<sup>R172H</sup>C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of <i>Npy1r</i> significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP<sup>R172H</sup>C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.

Authors

Institutions

Publication Details

Journal
Science Advances
Published
2025-03-12
DOI
https://doi.org/10.1126/sciadv.adq4416
Citations
5
Primary Topic
Cancer, Stress, Anesthesia, and Immune Response
Type
article
Field-Weighted Citation Impact
7.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis

Daniel Christ, Ben Crossett, Alice Tran, Nicola Waddell et al.
5 citations
Science Advances
Cancer, Stress, Anesthesia, and Immune Response
7.36
article

Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis

Daniel Christ, Ben Crossett, Alice Tran, Nicola Waddell, Jennifer P. Morton, Yan‐Chuan Shi, Janett Stoehr, Max Nobis, Mark Pinese, Lea Abdulkhalek, Thomas R. Jeffry Evans, Jaswinder Singh Samra, Anaiis Zaratzian, Xanthe L. Metcalf, Claire Vennin, Angela Connolly, Leonard D. Goldstein, Pauline Mélénec, Thi Hai Yen Tran, Andrew Da Silva, Hao‐Wen Sim, Diego Chacon Fajardo, Robert J. Weatheritt, Andrew Philp, Tatyana Chtanova, Anthony James Gill, Thomas R. Cox, Anubhav Mittal, Alexander W. Rookyard, Astrid Magenau, Daniel A. Reed, Lily M. Channon, David R. Croucher, Shona Ritchie, Gonzalo del Monte‐Nieto, Michael Tayao, Victoria M. Tyma, Michael Trpceski, Antonia L. Cadell, Paul Timpson, Yingxiao Wang, David Herrmann, Jake Y. Henry, Victoria Lee, Lorraine A. Chantrill, Marina Pajic, Ashleigh Dale, Kendelle J. Murphy, Cecilia R. Chambers, Marija Dinevska, Brooke Pereira, Anthony M. Joshua, Herbert Herzog, Jessie Zhu, Jessica L. Chitty, Peter Kaltzis, Lei Zhang, Anna E. Howell, Peter M. Schofield, Ruth J. Lyons, Sean M. O’Connell, Ronaldo F. Enriquez, Supitchaya Watakul, Nadia Kuepper
article en
5 citations

Abstract

Pancreatic cancer (PC) is a highly metastatic malignancy. More than 80% of patients with PC present with advanced-stage disease, preventing potentially curative surgery. The neuropeptide Y (NPY) system, best known for its role in controlling energy homeostasis, has also been shown to promote tumorigenesis in a range of cancer types, but its role in PC has yet to be explored. We show that expression of NPY and <i>NPY1R</i> are up-regulated in mouse PC models and human patients with PC. Moreover, using the genetically engineered, autochthonous KP<sup>R172H</sup>C mouse model of PC, we demonstrate that pancreas-specific and whole-body knockout of <i>Npy1r</i> significantly decreases metastasis to the liver. We identify that treatment with the NPY1R antagonist BIBO3304 significantly reduces KP<sup>R172H</sup>C migratory capacity on cell-derived matrices. Pharmacological NPY1R inhibition in an intrasplenic model of PC metastasis recapitulated the results of our genetic studies, with BIBO3304 significantly decreasing liver metastasis. Together, our results reveal that NPY/NPY1R signaling is a previously unidentified antimetastatic target in PC.

Science AdvancesVol. 11(11)
University of Technology Sydney (AU), University of Southern California (US), The University of Sydney (AU), Garvan Institute of Medical Research (AU), The University of Melbourne (AU), QIMR Berghofer Medical Research Institute (AU), Royal North Shore Hospital (AU), Centenary Institute (AU), Australian Regenerative Medicine Institute (AU), Cancer Research UK (GB), Cancer Institute of New South Wales (AU), UNSW Sydney (AU), St Vincent's Hospital Sydney (AU), Illawarra Shoalhaven Local Health District (AU), VIB-KU Leuven Center for Cancer Biology (BE), Children's Cancer Institute Australia (AU), St Vincent's Clinic (AU), La Jolla Bioengineering Institute (US), National Health and Medical Research Council (AU), Monash University (AU), University of Glasgow (GB)
Good health and well-being
Openalex Percentile: Top 3%
Cancer, Stress, Anesthesia, and Immune Response
7.36
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.